Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $19.50.

A number of research firms recently issued reports on ZVRA. William Blair restated an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Maxim Group boosted their target price on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Monday, April 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Zevra Therapeutics in a report on Wednesday, April 3rd.

Zevra Therapeutics Stock Up 0.7 %

Shares of NASDAQ ZVRA opened at $4.58 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.08. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $7.28. The firm has a 50-day moving average price of $5.58 and a 200 day moving average price of $5.37. The stock has a market capitalization of $198.91 million, a price-to-earnings ratio of -3.55 and a beta of 1.81.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.20). The business had revenue of $13.22 million for the quarter, compared to analyst estimates of $13.35 million. Zevra Therapeutics had a negative return on equity of 68.41% and a negative net margin of 167.69%. Equities research analysts anticipate that Zevra Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds have recently made changes to their positions in ZVRA. VisionPoint Advisory Group LLC purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $33,000. Strs Ohio acquired a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $37,000. International Assets Investment Management LLC increased its stake in Zevra Therapeutics by 555.0% in the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after buying an additional 5,550 shares during the period. Commonwealth Equity Services LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $52,000. Finally, Kingsview Wealth Management LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $58,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.